Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, announced that President and CEO Todd C. Brady will speak at the H.C. Wainwright Global Investment Conference. The fireside chat, featuring Vice President of Equity Research Matthew Caufield, will be available on demand starting 7:00 a.m. ET on May 24, 2022. Interested viewers can access the event through the Investors & Media section on Aldeyra's website, which will be archived for 90 days. Aldeyra's leading products include reproxalap and ADX-629, targeting immune-inflammation.
Aldeyra Therapeutics (ALDX) announced positive findings from a post-hoc analysis of the Phase 3 TRANQUILITY trial for reproxalap, indicating statistical superiority (p=0.020) in reducing ocular redness, the primary endpoint. This follows a similar confirmation in the Phase 2 trial (p=0.003). Aldeyra plans to engage with the FDA, including ocular redness as an objective sign in its upcoming New Drug Application (NDA) expected mid-2022, contingent on discussions and outcomes from the ongoing TRANQUILITY-2 trial.
Aldeyra Therapeutics (Nasdaq: ALDX) reported its financial results for Q1 2022, with cash holdings of $216.9 million, expected to cover operations through 2023. The company completed enrollment for the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease, with results anticipated in Q2 2022. Positive top-line data from Phase 2 trials of ADX-629 were also announced, leading to new indications in ethanol toxicity and chronic cough. Despite a net loss of $16.8 million, up from $11.3 million year-over-year, Aldeyra continues to progress in clinical trials across various indications.
Aldeyra Therapeutics (NASDAQ: ALDX) will be represented by Kelly Mizer, Vice President, at the MOD Live! 2022 meeting in Nashville, Tennessee, from May 5-7, 2022. The event focuses on innovative therapies in optometry, particularly in the session titled 'The Future of Optometry – Pipeline Game Changers'. Mizer will provide updates on reproxalap, an investigational drug in Phase 3 trials aimed at treating dry eye disease and allergic conjunctivitis.
Aldeyra specializes in therapies for immune-mediated diseases, with a focus on RASP modulators.
Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on May 5, 2022, at 8:00 a.m. ET to discuss its financial results for Q1 2022, ending March 31, 2022. The call can be accessed via dial-in numbers for both domestic and international callers, with an access code provided. A live audio webcast will be available on Aldeyra's website, and the archived event will remain accessible for 90 days. Aldeyra focuses on therapies for immune-mediated diseases and has several clinical candidates in various stages, including reproxalap and ADX-629.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has announced the presentation of results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial of reproxalap for dry eye disease at the 2022 ASCRS Annual Meeting on April 23, 2022. Reproxalap is a first-in-class small-molecule modulator targeting reactive aldehyde species, currently in Phase 3 development. The company aims to provide innovative therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis, significant markets in ophthalmology.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced the completion of enrollment in the Phase 3 TRANQUILITY-2 Trial for its investigational drug, reproxalap, aimed at treating dry eye disease. The multi-center study enrolled 361 patients and measured tear volume and ocular redness as primary endpoints. Top-line results are expected this quarter, and if successful, the data could support a New Drug Application (NDA) submission. Aldeyra plans to utilize data from completed clinical trials to meet FDA regulatory requirements.
Aldeyra Therapeutics announced promising signs of clinical activity for ADX-629 in three Phase 2 trials aimed at immune-mediated diseases. No safety issues were reported, and the company plans to expand ADX-629's development into new indications, including ethanol toxicity and chronic cough. Key results showed significant decreases in inflammation-related metrics in psoriasis, asthma, and COVID-19 patients. The company will present additional findings and plans during its R&D Day and expects to initiate new trials in 2023.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will hold a Research & Development Day on March 29, 2022, from 10:00 a.m. to 12:30 p.m. ET in New York City. The event will reveal top-line data from Phase 2 clinical trials of ADX-629, a first-in-class orally administered RASP modulator, targeting three inflammatory diseases. Presentations will feature Aldeyra's senior leadership and Dr. Geoffrey M. Thiele from the University of Nebraska Medical Center. A live webcast will be available on their website, with replays for 90 days.
Aldeyra Therapeutics (ALDX) reported its financial results for 2021, highlighting a net loss of $57.8 million, or $1.07 per share, compared to $37.6 million, or $1.11 per share in 2020. The increase in loss is attributed to higher costs in clinical trials and R&D, totaling $44.9 million. As of December 31, 2021, cash and cash equivalents stood at $229.8 million, projected to support operations through 2023. Upcoming milestones include top-line data from ADX-629 trials by March 2022 and results from various Phase 3 trials for reproxalap and ADX-2191 expected throughout 2022.